The REAL-CAD Study in 13,054 Patients

Slides:



Advertisements
Similar presentations
Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.
Advertisements

1. 2 The primary Objective of IDEAL LDL-C Simvastatin mg/d Atorvastatin 80 mg/d risk CHD In stable CHD patients IDEAL: The Incremental Decrease.
Henry C. Ginsberg, MD College of Physicians & Surgeons, Columbia University, New York For The ACCORD Study Group.
Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.
ASTEROID A Study To evaluate the Effect of Rosuvastatin On Intravascular ultrasound- Derived coronary atheroma burden.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
Slide Source: Lipids Online Slide Library Collaborative Atorvastatin Diabetes Study (CARDS) Type 2 diabetes mellitus Men and women.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.
The Prospective Pravastatin Pooling Project L I P I D CARECARE PPP Project Investigators Am J Cardiol 1995; 76:899–905.
SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.
On-Treatment Analysis A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet)
4S: Scandinavian Simvastatin Survival Study
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)
US cost-effectiveness of simvastatin in 20,536 people at different levels of vascular disease risk: randomised placebo-controlled trial UK Medical Research.
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Ungroup once.
Title slide.
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
The American College of Cardiology Presented by Dr. Steven E. Nissen
The Importance of Adequately Powered Studies
HOPE: Heart Outcomes Prevention Evaluation study
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.
Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes Louise Bowman & Martin Landray on.
The American Heart Association Presented by Dr. Steven E. Nissen
LDL Cholesterol Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial Marc P. Bonaca, Patrice.
The Anglo Scandinavian Cardiac Outcomes Trial
The REAL-CAD Study in 13,054 Patients
POISE-2 PeriOperative ISchemic Evaluation-2 Trial
PS Sever, PM Rothwell, SC Howard, JE Dobson, B Dahlöf,
AIM HIGH Niacin plus Statin to prevent vascular events
HDL cholesterol and cardiovascular risk Epidemiological evidence
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
First time a CETP inhibitor shows reduction of serious CV events
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Scandinavian Simvastatin Survival Study (4S)
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
The following slides highlight a presentation at the Late-Breaking Clinical Trials session of the American Heart Association Scientific Sessions, November.
Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?
Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Dabigatran in myocardial injury after noncardiac surgery
Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.
The results of the SHARP trial
Statins Evaluation in Coronary procedUres and REvascularization
These slides highlight an educational report from a late-breaking clinical trials presentation at the 58th Annual Scientific Session of the American College.
Section 7: Aggressive vs moderate approach to lipid lowering
This series of slides highlights a report based on a presentation at the Late-Breaking Trial Sessions of the 2005 American Heart Association Scientific.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Lipid-Lowering Arm (ASCOT-LLA): Results in the Subgroup of Patients with Diabetes Peter S. Sever, Bjorn Dahlöf, Neil Poulter, Hans Wedel, for the.
These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.
LRC-CPPT and MRFIT Content Points:
Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter
The results of the SHARP trial
The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Presentation transcript:

Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? The REAL-CAD Study in 13,054 Patients With Stable Coronary Artery Disease Takeshi Kimura, Teruo Inoue, Isao Taguchi, Hiroshi Iwata, Satoshi Iimuro, Takafumi Hiro, Yoshihisa Nakagawa, Yukio Ozaki, Yasuo Ohashi, Hiroyuki Daida, Hiroaki Shimokawa, Ryozo Nagai, on behalf of the REAL-CAD Study Investigators Disclosure: Public Health Research Foundation, Kowa Pharmaceutical Co. Ltd.

ACC/AHA guideline: High-intensity statin therapy Backgrounds Recommendations for Lipid-lowering Therapy in Patients with Established CAD ACC/AHA guideline: High-intensity statin therapy atorvastatin 40/80mg, rosuvastatin 20/40mg, or simvastatin 80mg Previous “More versus Less” Statins Trials LDL-C Reduction (mmol/L) Events (% per annum) Unweighted RR (CI) Statin/more Control/less More vs less statin PROVE−IT TNT IDEAL SEARCH A to Z 0.65 0.62 0.55 0.39 0.30   406 (11.3%) 889 (4.0%) 938 (5.2%) 1,347 (3.6%) 257 (7.2%)   458 (13.1%) 1,164 (5.4%) 1,106 (6.3%) 1,406 (3.8%) 282 (8.1%) Trend: χ21=12.4 (p=0.0004) Subtotal (5 trials) 0.51 3,837/19,829 (4.5%) 4,416/19,783 (5.3%) 0.85 (0.82-0.89) p<0.0001 Cholesterol Treatment Trialists’ (CTT) Collaboration. Lancet 2010; 376: 1670-81.

Backgrounds and Objectives However, the high-intensity statins are not widely used in daily clinical practice, particularly in Asia. No clear evidence regarding “more versus less” statins has been established in Asian population. Most of the doses of high-intensity statin therapy defined in the ACC/AHA guideline are not approved in Japan. Furthermore, maximum approved doses of statins are prescribed only very infrequently in Japan. Therefore, we sought to determine whether higher-dose statin therapy would be beneficial in Japanese patients in the largest-ever trial comparing the efficacy of high-dose versus low-dose statin therapy in patients with established stable CAD.

Run-in Period (>1 month) REAL-CAD (Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy with Pitavastatin in Coronary Artery Disease) A prospective, multi-center, randomized, open-label, blinded endpoint, physician-initiated trial to determine whether high-dose as compared with low-dose pitavastatin therapy within the approved dose range could reduce CV events in Japanese patients with stable CAD. ・Men and women, 20-80years of age ・Stable CAD: ・ACS or PCI/CABG >3months ・Clinical diagnosis of CAD with coronary stenosis ≥50% diameter stenosis ・LDL-C <120mg/dL on pitavastatin 1mg/day during the run-in period Eligibility: Pitavastatin 1mg/day Consent for enrollment Pitavastatin 1mg/day Randomization Pitavastatin 4mg/day Jan. 2010 ~ Mar. 2013 LDL-C <120mg/dL Jan. ~ Mar. 2016 Run-in Period (>1 month) Follow-up (36-60 months) Pitavastatin 1mg and 4mg have LDL-C lowering effect comparable to atorvastatin 5mg and 20mg, respectively.

Study Design Primary Endpoint Sample size calculation a composite of CV death, non-fatal MI, non-fatal ischemic stroke, or unstable angina requiring emergency hospitalization Sample size calculation Hypothesis: 16% relative risk reduction with the high-dose pitavastatin Tx Assumptions: Annual primary endpoint event rate of 2.5%, Drop-out rate of 10% Sample size: 12,600 patients were to be enrolled with anticipated 1,033 events during the planned 3 years of enrollment and at least 3 years of follow-up. Power: 80%, Alpha: 0.05 The actual event rate was lower than anticipated. On October 27, 2015, the steering committee decided not to extend the study further despite the original event-driven trial design, because substantial number of centers were reluctant to extend the study further.

Study Patient Flow Enrolled N=14,774 Randomized N=13,054 Jan. 2010 – Mar. 2013 733 Japanese centers Enrolled N=14,774 Excluded N=1,720 Withdrawal/Missing consent N=790 Other reasons N=930 Randomized N=13,054 Pitavastatin 1mg N=6,528 Pitavastatin 4mg N=6,526 Withdrawal/Missing consent N=100 Withdrawal/Missing consent N=136 Safety analysis set (SAS) N=6,428 Safety analysis set (SAS) N=6,390 Not meeting the eligibility N=214 ACS within 3 months N=35 LDL-C <100 mg/dL without statins N=76 LDL-C ≥120 mg/dL at randomization N=105 Not meeting the eligibility N=191 ACS within 3 months N=16 LDL-C <100 mg/dL without statins N=76 LDL-C ≥120 mg/dL at randomization N=101 Full analysis set (FAS) N=6,214 Full analysis set (FAS) N=6,199 Follow-up period [median]: 3.9 (0.0-5.9) years 1 year FU completed: 96.9%  Final FU completed beyond Jan. 2016: 83.2% Follow-up period [median]: 3.9 (0.0-5.8) years 1 year FU completed: 97.0%  Final FU completed beyond Jan. 2016: 83.4%

Baseline Characteristics Variables Pitavastatin 1 mg (N=6,214) Pitavastatin 4 mg (N=6,199) Age — years 68.1±8.3 68.0±8.3 Male sex 83% BMI — kg/m2 24.6±3.4 24.6±3.3 Hypertension 75% 76% Diabetes mellitus 40% Current smoking 16% 17% History of ACS 72% ACS within 1 year before randomization 24% Coronary revascularization 91% 90% Revascularization within 1 year before randomization 28% Ischemic stroke 7% Peripheral vascular disease CKD (eGFR <60 mL/min/1.73m2) 36% 35% Aspirin 93% 92% DAPT 45% 44% Statins before enrollment

Serial Changes in Lipid Parameters and hs-CRP 100 Pitavastatin 1 mg LDL-C 55 HDL-C Pitavastatin 4 mg 95 89.4 91.1 91.1 91.0 54 90 88.1 53 52.2 52.3 52.3 LDL-C (mg/dL) 85 87.7 HDL-C (mg/dL) 52 80 50.7 51.0 76.6 75 51 51.7 76.6 51.6 51.6 75.5 73.7 70 Main effect p< 0.001 50 50.7 50.6 Main effect p< 0.001 Interaction p< 0.001 Interaction p= 0.17 Baseline 0.5 1 2 3 Baseline 0.5 1 2 3 No. of Patients Years No. of Patients Years 1 mg 6,214 6,031 5,615 5,252 4,509 1 mg 6,212 6,028 5,596 5,238 4,498 4 mg 6,199 5,890 5,518 5,203 4,405 4 mg 6,198 5,890 5,482 5,174 4,388 130 127.1 TG 0.65 hs-CRP 125.5 0.59 0.59 125 122.3 122.4 121.5 0.60 125.4 TG (mg/dL) 120 hs-CRP (mg/L) 0.55 0.57 115 117.5 0.50 114.5 115.0 114.5 0.49 110 Main effect p< 0.001 0.45 Interaction p= 0.77 Main effect p< 0.001 Baseline 0.5 1 Years 2 3 Baseline Months 6 No. of Patients No. of Patients 1 mg 6,208 6,032 5,606 5,245 4,507 1 mg 6,032 5,734 4 mg 6,195 5,896 5,498 5,183 4,402 4 mg 5,994 5,585

Primary Endpoint (CV death/ MI/ Ischemic stroke/ UA) 10 HR 0.81 (95% CI, 0.69-0.95), Cox P=0.01 No. of patients with event: 4 mg 266 (4.3%), 1 mg 334 (5.4%) 8 NNT for 5 years=63 5.6 6 log-rank P=0.01 Pitavastatin 1 mg Cumulative incidence(%) 4.2 Pitavastatin 4 mg 4 4.6 2.9 3.5 2 1.4 2.3 1.2 1 2 3 4 5 No. at risk Years 1 mg 6,214 5,743 5,321 4,501 2,760 593 4 mg 6,199 5,631 5,256 4,427 2,730 616

Primary Endpoint plus Coronary Revascularization* Secondary Endpoint Primary Endpoint plus Coronary Revascularization* 20 HR 0.83 (95% CI, 0.73-0.93), Cox P=0.002 18 No. of patients with event: 4 mg 489 (7.9%), 1 mg 600 (9.7%) 16 14 NNT for 5 years=41 12 10.4 Pitavastatin 1 mg log-rank P=0.002 Cumulative incidence(%) 10 Pitavastatin 4 mg 8.0 8 5.8 8.5 6 6.7 4 2.8 4.7 2 2.5 : Excluding TLR for lesions treated at prior PCI * 1 2 3 4 5 No. at risk Years 1 mg 6,214 5,660 5,166 4,327 2,627 561 4 mg 6,199 5,556 5,131 4,277 2,617 588

Other Secondary Endpoints No. of patients with event (%) 1mg (n=6,214) 4mg (n=6,199) Outcomes HR(95% CI) P Value Death from any cause CV death MI Ischemic stroke Hemorrhagic stroke Unstable angina requiring emergency hospitalization Coronary revascularization (All) Coronary revascularization (non-TLR) Coronary revascularization (TLR) 260 (4.2) 112 (1.8) 72 (1.2) 83 (1.3) 30 (0.5) 90 (1.4)   626 (10.1) 356 (5.7) 319 (5.1) 207 (3.3) 86 (1.4) 40 (0.6) 84 (1.4) 43 (0.7) 76 (1.2) 529 (8.5) 277 (4.5) 276 (4.5) 0.81 (0.68-0.98) 0.78 (0.59-1.04) 0.57 (0.38-0.83) 1.03 (0.76-1.40) 1.46 (0.92-2.33) 0.86 (0.63-1.17) 0.86 (0.76-0.96) 0.79 (0.68-0.92) 0.88 (0.75-1.03) 0.03 0.09 0.004 0.84 0.11 0.34 0.008 0.003 0.12 4 mg Better 1 1 mg Better

Subgroup Analyses Primary Endpoint (CV death/ MI/ Ischemic stroke/ UA) No. of patients Event rate (%) P value for interaction Subgroup 1 mg 4 mg HR (95% CI) Overall Age Sex Diabetes LDL-C hs-CRP HDL-C TG BMI < 65 ≥ 65 Male Female Yes No < 95 mg/dL ≥ 95 mg/dL < 1 mg/L ≥ 1 mg/L ≤ 40 mg/dL > 40 mg/dL < 150 mg/dL ≥ 150 mg/dL < 25 ≥ 25 12,413 4,009 8,404 10,253 2,160 4,978 7,435 7,865 4,548 8,510 3,516 2,607 9,803 8,045 4,358 6,693 4,788 5.4 5.0 5.6 5.7 3.8 6.5 4.6 5.0 5.9 4.9 6.7 6.5 5.1 5.1 5.9 5.3 5.7 4.3 3.3 4.8 4.6 3.0 4.8 4.0 4.0 4.8 3.6 6.0 5.0 4.1 4.3 4.2 4.5 4.4 0.81 (0.69-0.95) 0.67 (0.49-0.91) 0.87 (0.72-1.05) 0.81 (0.68-0.96) 0.81 (0.51-1.28) 0.75 (0.59-0.95) 0.86 (0.69-1.08) 0.81 (0.66-1.00) 0.81 (0.63-1.05) 0.75 (0.61-0.92) 0.89 (0.68-1.16) 0.78 (0.56-1.08) 0.82 (0.68-0.99) 0.86 (0.70-1.06) 0.73 (0.56-0.96) 0.87 (0.70-1.07) 0.78 (0.60-1.00) 0.16 0.99 0.39 0.97 0.32 0.78 0.34 0.53 1 4 mg Better 1 mg Better

Safety Outcomes Event Adverse events—N (%) Rhabdomyolysis 1 (0.0) Pitavastatin 1 mg (N=6,428) Pitavastatin 4 mg (N=6,390) P value Adverse events—N (%) Rhabdomyolysis 1 (0.0) 2 (0.0) 0.62 Muscle-complaints 45 (0.7) 121 (1.9) <0.001 New onset of diabetes mellitus 279 (4.3) 285 (4.5) 0.76 Laboratory test abnormalities—N (%) Elevation of ALT, AST, or both ≥3ULN 174 (2.7) 187(2.9) 0.46 Elevation of CK ≥5ULN 40 (0.6) 42 (0.7) 0.83 Study drug discontinuation—N (%) 503 (8.1) 610 (9.8)

Study Limitations The present study was conducted as an open-label trial with its inherent limitations. However, considering the limitations of the open-label trial design, the primary endpoint was defined as not including coronary revascularization procedures. The present study was prematurely terminated despite the original event- driven trial design, although we observed significant risk reduction for the primary endpoint. 3. Final follow-up was not completed in a substantial proportion of patients, reflecting a limitation of physician-initiated study relying upon voluntary efforts of the site investigators.

Conclusions and Implications High-dose (4 mg/day) as compared with low-dose (1 mg/day) pitavastatin therapy significantly reduced CV events in Japanese patients with stable CAD. The present study suggests that the administration of maximum tolerable doses of statins within the range of local approval would be the preferred statins therapy in Japanese patients with established CAD regardless of the baseline LDL-C levels.